| Identification | Back Directory | [Name]
2(5H)-Furanone, 5-acetyl-3-hydroxy-5-[[4-hydroxy-3-(3-methyl-2-buten-1-yl)phenyl]methyl]-4-(4-hydroxyphenyl)-, (5R)- | [CAS]
2758569-43-4 | [Synonyms]
2(5H)-Furanone, 5-acetyl-3-hydroxy-5-[[4-hydroxy-3-(3-methyl-2-buten-1-yl)phenyl]methyl]-4-(4-hydroxyphenyl)-, (5R)- | [Molecular Formula]
C24H24O6 | [MOL File]
2758569-43-4.mol | [Molecular Weight]
408.44 |
| Chemical Properties | Back Directory | [Boiling point ]
671.2±55.0 °C(predicted) | [density ]
1.329±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | [pka]
8.62±0.40(predicted) |
| Hazard Information | Back Directory | [Uses]
BTL-MK (Compound 19) an orally active antiallergic agent, that inhibits degranulation of mast cells with an IC50 of 6.7 μM, through binding to the inhibitory receptor FcγRIIB. BTL-MK improves the metaboilic stability in human liver microsomes. BTL-MK ameliorates the allergic response in Ovalbumins (HY-W250978)-induced food allergy mice model. BTL-MK exhibits a good pharmacokinetic character with metabolic stability[1]. | [References]
[1] Xie CL, et al., Lead Optimization of Butyrolactone I as an Orally Bioavailable Antiallergic Agent Targeting FcγRIIB. J Med Chem. 2024 May 9;67(9):7504-7515. DOI:10.1021/acs.jmedchem.4c00354 |
|
|